Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: A potential target for the treatment of Crohn's disease

Mucosal Immunology

Volumn 5, Issue 2, 2012, Pages 129-139

  Lawrenz, M ^a   Visekruna, A ^a,b   Kuhl A ^c   Schmidt, N ^a   Kaufmann, S H E ^a   Steinhoff, U ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROGRESSION LOCUS 2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE SEVERITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INTESTINE FLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTO ONCOGENE; TUMOR PROGRESSION LOCUS 2 GENE; ULCERATIVE COLITIS;

EID: 84857222716     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.57     Document Type: Article

References (37)

1. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003). (Pubitemid 37328672)
2. Cho, J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458-466 (2008). (Pubitemid 351733422)
3. Podolsky, D.K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002). (Pubitemid 34851835)
4. Kaser, A., Zeissig, S. & Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
5. Beinke, S. et al. NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol. Cell Biol. 23, 4739-4752 (2003). (Pubitemid 36793322)
6. Feldmann, M. & Maini, R.N. Anti-TNF-alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001). (Pubitemid 32368033)
7. Girardin, S.E., Hugot, J.P. & Sansonetti, P.J. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24, 652-658 (2003). (Pubitemid 37485915)
8. Neurath, M.F., Pettersson, S., Meyer zum Buschenfelde, K.H. & Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2, 998-1004 (1996). (Pubitemid 26306838)
9. Rogler, G. et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357-369 (1998). (Pubitemid 28363428)
10. Patriotis, C., Makris, A., Bear, S.E. & Tsichlis, P.N. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc. Natl. Acad. Sci. USA 90, 2251-2255 (1993). (Pubitemid 23078604)
11. Salmeron, A., Ahmad, T.B ., Carlile, G.W., Pappin, D ., Narsimhan, R.P. & Ley, S.C. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 15, 817-826 (1996).
12. Dumitru, C.D. et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071-1083 (2000). (Pubitemid 32040907)
13. Mielke, L.A. et al. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J. Immunol. 183, 7984-7993 (2009).
14. Wirtz, S., Neufert, C., Weigmann, B. & Neurath, M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546 (2007). (Pubitemid 47040018)
15. Wang, D., Dubois, R.N. & Richmond, A. The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol. 9, 688-696 (2009).
16. Rousseau, S. et al. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J. Cell Sci. 121, 149-154 (2008). (Pubitemid 351228446)
17. Rasola, A., Sciacovelli, M., Chiara, F., Pantic, B., Brusilow, W.S. & Bernardi, P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc. Natl. Acad. Sci. USA 107, 726-731 (2010).
18. Saleh, M. & Trinchieri, G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat. Rev. Immunol. 11, 9-20 (2011).
19. Schreiber, S. et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 353, 459-461 (1999). (Pubitemid 29067338)
20. Visekruna, A. et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J. Clin. Invest. 116, 3195-3203 (2006).
21. Kontoyiannis, D. et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn'slike inflammatory bowel disease. J. Exp. Med. 196, 1563-1574 (2002).
22. Axelsson, L.G., Landstrom, E., Goldschmidt, T.J., Gronberg, A. & Bylund-Fellenius, A.C. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK-cell depleted SCID mice. Inflamm. Res. 45, 181-191 (1996). (Pubitemid 26135074)
23. Smythies, L.E. et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75 (2005). (Pubitemid 40385506)
24. Arpinati, M., Green, C.L., Heimfeld, S., Heuser, J.E. & Anasetti, C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95, 2484-2490 (2000). (Pubitemid 30210524)
25. Kared, H., Masson, A., Adle-Biassette, H., Bach, J.F., Chatenoud, L. & Zavala, F. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells. Diabetes 54, 78-84 (2005). (Pubitemid 40105097)
26. Reinecker, H.C. et al. Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181 (1993).
27. Villani, A.C. et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41, 71-76 (2009).
28. Zaki, M.H., Lamkanfi, M. & Kanneganti, T.D. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol. 32, 171-179 (2011).
29. Waterfield , M.R. , Zhang , M. , Norman , L.P. & Sun , S.C. NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase . Mol. Cell. 11 , 685 - 694 ( 2003 ). (Pubitemid 36385122)
30. Guma, M. et al. Constitutive intestinal NF-{kappa}B does not trigger destructive inflammation unless accompanied by MAPK activation. J. Exp. Med. 208, 1889-1900 (2011).
31. Gantke, T., Sriskantharajah, S. & Ley, S.C. Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res. 21, 131-145 (2011).
32. Das, S. et al. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J. Biol. Chem. 280, 23748-23757 (2005).
33. Cohen, P. Targeting protein kinases for the development of antiinflammatory drugs. Curr. Opin. Cell Biol. 21, 317-324 (2009).
34. George, D. et al. Discovery of thieno[2,3-c]pyridines as potent COT inhibitors. Bioorg. Med. Chem. Lett. 18, 4952-4955 (2008).
35. Hall, J.P. et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J. Biol. Chem. 282, 33295-33304 (2007).
36. Hu, Y. et al. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 16, 6067-6072 (2006).
37. Waetzig, G.H., Seegert, D., Rosenstiel, P., Nikolaus, S. & Schreiber, S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 168, 5342-5351 (2002). (Pubitemid 34496003)